Cardiometabolic risks in PCOS: a review of the current state of knowledge

References

• Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36:487–525.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375:54–64.
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
   PubMed Web of Science ®Google Scholar
• Palomba S, Santagni S, Falbo A, et al. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745–763.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao H, Chen ZJ. Genome-wide association studies for polycystic ovary syndrome. Semin Reprod Med. 2016;34:224–229.
   PubMed Web of Science ®Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3236–3242.
   PubMed Web of Science ®Google Scholar
• Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod (Oxford, England). 2001;16:1995–1998.
   PubMed Web of Science ®Google Scholar
• Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod (Oxford, England). 2016;31:2619–2631. Pub Med: 27907900.
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum Reprod. 2013;28:777–784.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
   PubMed Web of Science ®Google Scholar
• Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618–637.
   PubMed Web of Science ®Google Scholar
• Barrea L, Marzullo P, Muscogiuri G, et al. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr Res Rev. 2018;31:1–11.
   Web of Science ®Google Scholar
• Joham AE, Ranasinha S, Zoungas S, et al. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:E447–52.
   PubMed Web of Science ®Google Scholar
• Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in pcos: a systematic review and meta-regression. Hum Reprod Update. 2018;24:455–467.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010;95:2038–2049.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (chd): a meta-analysis. Oncotarget. 2016;7:33715–33721.
   PubMedGoogle Scholar
• Group REA-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (Oxford, England). 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Copyright Monash University, Melbourne Australia; 2018.
   Google Scholar
• Health NIO. Evidence-based methodology workshop on polycystic ovary syndrome 2012; Executive summary. [cited 2018 Mar 1]. Available at: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf.
   Google Scholar
• Teede HJ, Costello MF, Dokras A, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod (Oxford, England). In press 2018.
   Web of Science ®Google Scholar
• Kar S. Anthropometric, clinical, and metabolic comparisons of the four rotterdam PCOS phenotypes: a prospective study of PCOS women. J Hum Reprod Sci. 2013;6:194–200.
   PubMedGoogle Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97:28–38.e25.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
   PubMed Web of Science ®Google Scholar
• Chang J, Azziz R, Legro R, et al. The rotterdam ESHRE/ASRM-sponsored pcos consensus workshop group (2004) revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25. DOI:10.1016/j.Fertnstert.2003.10.004
   Google Scholar
• Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007;8:127–141.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Yang WS, Yang JH, et al. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension (Dallas, Tex: 1979). 2007;49:1442–1447.
   PubMed Web of Science ®Google Scholar
• Holte J, Gennarelli G, Berne C, et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod. 1996;11:23–28.
   PubMed Web of Science ®Google Scholar
• Moretti C, Lanzolla G, Moretti M, et al. Androgens and hypertension in men and women: a unifying view. Curr Hypertens Rep. 2017;19:44.
   PubMed Web of Science ®Google Scholar
• Joham A, Ranasinha S, Zoungas S, et al. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:E447-52.
   Google Scholar
• Kakoly NS, Earnest A, Moran LJ, et al. Group-based developmental BMI trajectories, polycystic ovary syndrome, and gestational diabetes: a community-based longitudinal study. BMC Med. 2017;15:195.
   PubMed Web of Science ®Google Scholar
• Couto Alves A, Valcarcel B, Makinen VP, et al. Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity. Int J Obesity (2005). 2017;41:1331–1340.
   Web of Science ®Google Scholar
• Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction (Cambridge, England). 2010;140:347–364.
   PubMed Web of Science ®Google Scholar
• Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E1088–96.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.
   PubMed Web of Science ®Google Scholar
• de Zegher F, Lopez-Bermejo A, Ibáñez L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab. 2009;20:418–423.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Lindholm C, Carlström K, et al. Reduced serum cholecystokinin response to food intake in female athletes. Metab Clin Exp. 1994;43:217–222.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Noakes M, Clifton PM, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab. 2004;89:3337–3344.
   PubMed Web of Science ®Google Scholar
• Wozniak M, Rydzewski B, Baker SP, et al. The cellular and physiological actions of insulin in the central nervous system. Neurochem Int. 1993;22:1–10.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Brown WJ, McNaughton SA, et al. Weight management practices associated with PCOS and their relationships with diet and physical activity. Hum Reprod (Oxford, England). 2017;32:669–678.
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod (Oxford, England). 2010;25:544–551.
   PubMed Web of Science ®Google Scholar
• Boudreaux MY, Talbott EO, Kip KE, et al. Risk of T2DM and impaired fasting glucose among pcos subjects: results of an 8-year follow-up. Curr Diab Rep. 2006;6:77–83.
   PubMedGoogle Scholar
• Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:66–71.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–363.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–4592.
   PubMed Web of Science ®Google Scholar
• Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome–a position statement of the androgen excess society. J Clin Endocrinol Metab. 2007;92:4546–4556.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30:S4–S41.
   PubMedGoogle Scholar
• Goodman NF, Cobin RH, Futterweit W, et al. American association of clinical endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015;21:1415–1426.
   PubMed Web of Science ®Google Scholar
• Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.  Obes Rev. 2018.  doi: 10.1111/obr.12762. [Epub ahead of print].
   Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53.
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821–826.
   PubMed Web of Science ®Google Scholar
• Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–951.
   PubMed Web of Science ®Google Scholar
• Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:3389–3394.
   PubMed Web of Science ®Google Scholar
• Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Dec 17 2002. 0009–7322.
   Google Scholar
• Glintborg D, Rubin KH, Nybo M, et al. Cardiovascular disease in a nationwide population of danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17:37.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother. 2011;12:13–30.
   PubMed Web of Science ®Google Scholar
• Kutkiene S, Petrulioniene Z, Laucevicius A, et al. Cardiovascular risk assessment of dyslipidemic middle-aged adults without overt cardiovascular disease over the period of 2009–2016 in Lithuania. Lipids Health Dis. 2018;17:233.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the interheart study): case-control study. Lancet (London, England). 2004;364:937–52.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Cameron J, et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4630–4635.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab. 1992;75:508–513.
   PubMed Web of Science ®Google Scholar
• Elting MW, Korsen TJM, Bezemer PD, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a dutch PCOS population. Hum Reprod. 2001;16:556–560.
   PubMed Web of Science ®Google Scholar
• Dumitrescu R, Mehedintu C, Briceag I, et al. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8:142–145.
   PubMedGoogle Scholar
• Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol. 2016;32:177–183.
   PubMed Web of Science ®Google Scholar
• Strand AH, Gudmundsdottir H, Os I, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006;24:905–913.
   PubMed Web of Science ®Google Scholar
• Dissen GA, Garcia-Rudaz C, Paredes A, et al. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology. 2009;150:2906–2914.
   PubMed Web of Science ®Google Scholar
• Heider U, Pedal I, Spanel-Borowski K. Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries. Fertil Steril. 2001;75:1141–1147.
   PubMed Web of Science ®Google Scholar
• Faulds G, Ryden M, Ek I, et al. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab. 2003;88:2269–2273.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak–the link between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9:526–539.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011;17:741–760.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048–58.e1–2.
   Web of Science ®Google Scholar
• Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab. 2008;93:82–90.
   PubMed Web of Science ®Google Scholar
• Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335–344.
   PubMed Web of Science ®Google Scholar
• Murri M, Luque-Ramirez M, Insenser M, et al. Circulating markers of oxidative stress and polycystic ovary syndrome (pcos): a systematic review and meta-analysis. Hum Reprod Update. 2013;19:268–288.
   PubMed Web of Science ®Google Scholar
• Krul-Poel YH, Snackey C, Louwers Y, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol. 2013;169:853–865.
   PubMed Web of Science ®Google Scholar
• Wehr E, Pilz S, Schweighofer N, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161:575–582.
   PubMed Web of Science ®Google Scholar
• Liu LC, Voors AA, van Veldhuisen DJ, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13:619–625.
   PubMed Web of Science ®Google Scholar
• Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–467.
   PubMed Web of Science ®Google Scholar
• Meyer ML, Malek AM, Wild RA, et al. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:112–126.
   PubMed Web of Science ®Google Scholar
• Johnson HM, Douglas PS, Srinivasan SR, et al. Predictors of carotid intima-media thickness progression in young adults: the bogalusa heart study. Stroke. 2007;38:900–905.
   PubMed Web of Science ®Google Scholar
• Calderon-Margalit R, Siscovick D, Merkin SS, et al. Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the coronary artery risk development in young adults women’s study. Arterioscler Thromb Vasc Biol. 2014:34:2688–2694. Pub Med: 25359859.
   PubMed Web of Science ®Google Scholar
• Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010;9:830–834.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Kihara Y, Higashi Y. Assessment of endothelium-independent vasodilation: from methodology to clinical perspectives. J Hypertens. 2018;36:1460–1467.
   PubMed Web of Science ®Google Scholar
• Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol (Oxf). 2013;78:438–446.
   PubMed Web of Science ®Google Scholar
• Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010;26:631–640.
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–448.
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Speirs A, Gould GW, et al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742–746.
   PubMed Web of Science ®Google Scholar
• Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78:773–776.
   PubMed Web of Science ®Google Scholar
• Bajuk Studen K, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018;7:R238–r51.
   PubMed Web of Science ®Google Scholar
• Chiu WL, Boyle J, Vincent A, et al. Cardiometabolic risks in polycystic ovary syndrome: non-traditional risk factors and the impact of obesity. Neuroendocrinology. 2017;104:412–424.
   PubMed Web of Science ®Google Scholar